Novartis hopes Kisqali data will help narrow gap to blockbuster rival

ZURICH (Reuters) – Novartis has released data showing sharply improved overall survival rates for its breast cancer drug Kisqali, which the Swiss drugmaker hopes will help it chip away at the dominance of Pfizer’s blockbuster Ibrance.

FILE PHOTO: The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel, Jan. 25, 2017. REUTERS/Arnd Wiegmann/File Photo

Novartis’s Kisqali had $235 million in sales in 2018, well behind the $4.1 billion for Ibrance, as Pfizer’s first-to-market drug captured the lion’s share of women with metastatic HR+/HER2- cancer.

The U.S. Food and Drug Administration approved Ibrance in February 2015, two years before Kisqali.

The data released on Saturday showed about 70 percent of pre-menopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer were alive 42 months after getting a cocktail of Kisqali and endocrine therapy.

That compares with 46 percent who received only endocrine therapy, which at the time of the study was the standard of care.

Doctors helping lead Novartis’s Kisqali study, called Monaleesa-7, said the statistically significant benefit it showed was good news for patients facing a challenging disease.

“To achieve overall survival improvement in an incurable disease, like metastatic breast cancer, is truly an outstanding advancement,” said Dr. Sara Hurvitz, head of breast cancer clinical trials at the University of California Los Angeles.

According to a Refinitiv poll, analysts expect Kisqali – priced at about $130,000 per year – to reap about $1.2 billion annually by 2024.

SURVIVAL ANALYSIS

The Swiss company is hoping its new survival analysis, released at the 2019 American Society of Clinical Oncology annual meeting in Chicago, will convince more doctors to consider Kisqali.

“Most physicians would practice evidence-based medicine, and in that case, having statistical significance certainly would have some persuasion in how they would actually move forward,” John Tsai, Novartis’ head global drug developer, said on a call.

Analysis of separate clinical trials is ongoing to determine potential overall survival benefit of taking Ibrance together with endocrine therapy, as well as of endocrine therapy with a similar drug, Eli Lilly’s Verzenio, that had $255 million in sales last year.

Kisqali, Ibrance and Verzenio have not been compared with each other in trials.

In addition to losing the race to market for Ibrance, Novartis’s Kisqali has faced some safety-linked hurdles.

Its label includes warnings for a possible heart condition, called QT prolongation, and liver toxicity that require monitoring that Pfizer’s medicine has avoided.

Kisqali, a CDK4/6 inhibitor that aims to halt hyperactive cellular machinery that drives tumour growth, is approved as an initial treatment for women with HR+/HER2- advanced or metastatic breast cancer, regardless of whether they have gone through menopause.

Ibrance and Lilly’s Verzenio have somewhat narrower first-line FDA labels, covering initial therapy for HR+/HER2- breast cancer in women after menopause.

Reporting by John Miller; Editing by David Holmes

Source

more recommended stories

  • Euthanasia law takes effect in Australia’s Victoria state

    MELBOURNE (Reuters) – Voluntary euthanasia became.

  • China to suspend pork imports from third Canadian firm as dispute with Ottawa deepens

    BEIJING (Reuters) – China will block.

  • U.S. records 22 new measles cases, bringing year’s total to 1,044

    (Reuters) – The United States recorded.

  • WHO likely to declare Ebola an international emergency: experts

    GENEVA (Reuters) – The World Health.

  • WHO panel decides not to declare international Ebola emergency

    GENEVA (Reuters) – A World Health.

  • U.S. drugmakers file lawsuit against requiring drug prices in TV ads

    FILE PHOTO: Used blister packets that.

  • Death toll from UK hospital listeria outbreak rises to five

    LONDON (Reuters) – The number of.

  • Female soldiers wanting to suppress periods face barriers

    (Reuters Health) – Military women wanting.

  • Chronic depression after heart attack tied to increased risk of death

    (Reuters Health) – Heart attack survivors.

  • North Korea steps up measures to prevent spread of African swine fever

    SEOUL (Reuters) – North Korea has.

  • Missouri’s only abortion clinic to stay open after injunction issued

    (Reuters) – The only abortion clinic.

  • China to tighten rules on foreigners using genetic material

    FILE PHOTO: A researcher inserts a.

  • Experimental drug delays type 1 diabetes onset in mid-stage trial

    (Reuters Health) – In people at.

  • Abbott device helps in cutting blood sugar in type 2 diabetics: study

    (Reuters) – Insulin-dependent patients with type.

  • USDA investigates unapproved GMO wheat found in Washington state

    CHICAGO (Reuters) – The U.S. Department.

  • As pressure for Afghan peace grows, drug threat remains

    KANDAHAR, Afghanistan (Reuters) – Mohammad Ahmadi,.

  • One in four Ebola cases undetected in Congo: WHO

    GENEVA (Reuters) – Roughly a quarter.

  • U.S. health agency cancels research contract involving use of fetal tissue

    (Reuters) – The Department of Health.

  • Many U.S. kids still eating laundry pods

    Many American children are still being.

  • Nipah virus resurfaces in India’s Kerala after killing 17 last year

    NEW DELHI (Reuters) – The deadly.

  • Therapy in the office: banks take mental health fight in-house

    LONDON (Reuters) – In ‘Billions’, a.

  • Lynparza stalls pancreatic cancer in patients with BRCA mutations: study

    CHICAGO (Reuters) – AstraZeneca and Merck.

  • Missouri abortion clinic to stay open for now after court order

    ST. LOUIS (Reuters) – Missouri’s only.

  • South Korea braces for African swine fever outbreak after North Korea case

    SEOUL (Reuters) – South Korea readied.

  • Louisiana governor to sign ‘heartbeat’ ban, latest move to curb U.S. abortion rights

    (Reuters) – Louisiana’s Democratic governor said.

  • UK institute, Belgian firm team up for African swine fever treatment

    LONDON (Reuters) – Britain’s Pirbright Institute.

  • Overweight teen boys have higher risk of heart muscle damage as adults

    (Reuters Health) – Men who were.

  • British Columbia to be first Canadian province to switch patients to biosimilars

    TORONTO/MONTREAL (Reuters) – The Canadian province.

  • Vietnam swine fever cull surges, 1.7 million pigs dead

    FILE PHOTO: Pork is displayed for.

  • Support for abortion rights grows as some U.S. states curb access – Reuters/Ipsos poll

    NEW YORK (Reuters) – Americans have.

  • Groups sue over Alabama abortion law; judge blocks Mississippi ban

    (Reuters) – The American Civil Liberties.

  • Novartis $2 million gene therapy for rare disorder is world’s most expensive drug

    ZURICH/NEW YORK – Swiss drugmaker Novartis.